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Interaction of Extracellular Matrix Protein 1 with
Extracellular Matrix Components: ECM1 Is a
Basement Membrane Protein of the Skin
Sandy Sercu1,6, Mei Zhang2,6, Noritaka Oyama3, Uwe Hansen4, Abdoel EL. Ghalbzouri5, Gu Jun2,
Kristof Geentjens1, Lurong Zhang2 and Joseph H. Merregaert1
The extracellular matrix protein 1 (ECM1) is a secreted glycoprotein, which plays an important role in the
structural and functional biology of the skin as demonstrated by the identification of loss-of-function mutations
in ECM1 as cause of the genodermatosis lipoid proteinosis, characterized by reduplication of the skin basement
membrane and hyalinization of the underlying dermis. To search for binding partner(s) of ECM1, we tested the
in vitro binding activity of ECM1a, a major isoform of four ECM1 splice variants, to different skin extracellular
matrix proteins (such as laminin 332, collagen type IV, and fibronectin) and polysaccharides (such as
hyaluronan, heparin, and chondroitin sulfate A) with solid-phase binding assay. We demonstrated that ECM1a
utilizes different regions to bind to a variety of extracellular matrix components. Ultrastructurally, ECM1 is a
basement membrane protein in human skin and is part of network-like suprastructures containing perlecan,
collagen type IV, and laminin 332 as constituents. Furthermore, ECM1a enhanced the binding of collagen IV to
laminin 332 dose-dependently, showing its involvement in the dermal–epidermal junction and interstitial dermis
and making the functional link to the pathophysiology of lipoid proteinosis. To our knowledge, this is
previously unreported.
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INTRODUCTION
Extracellular matrix proteins, such as the extracellular matrix
protein 1 (ECM1), play an important role in the extracellular
matrix formation, cell adhesion, cell signaling, and regulation
of tissue differentiation and/or maturation (Uitto, 2001; Pai
et al., 2002; Smith, 2003). This is exemplified by mutations of
the ECM1 gene, leading to its functional loss, as the cause of a
rare autosomal-recessive genodermatosis, lipoid proteinosis,
also known as hyalinosis cutis et mucosae or Urbach–Wiethe
disease (OMIM 247100) (Urbach, 1929; Hamada et al., 2002,
2003). This disease is characterized by generalized thickening
of the skin and mucosal infiltration with scarring. Histologi-
cally, these patients show vascular anomalies that represent
severe functional defects, caused by an excessive deposition of
hyaline-like (glassy) material (such as collagen IV and laminin
(LN)), which presumably lead to the disruption/reduplication
of the basement membrane and the underlying dermal
blood vessels (Fleischmajer et al., 1984; Harper et al., 1985;
Kowalewski et al., 2005; Mirancea et al., 2006, 2007). In spite
of extensive clinical studies, including molecular genetics,
there is still very limited knowledge on the actual mole-
cular interactions and their consequences on the basement
membrane or cell and tissue properties in lipoid protei-
nosis. Nevertheless, these abnormalities suggest that ECM1
might have a regulatory role in maintaining skin integrity.
Recent studies identified auto-antibodies against the ECM1
protein in the inflammatory mucocutaneous disorder, lichen
sclerosus, characterized by fragility and hyalinization of the
upper dermis (Oyama et al., 2003, 2004; Chan et al., 2004a).
Further clues to the physiological role of ECM1 have been
suggested by the discovery of interactions with perlecan
(Mongiat et al., 2003), fibulin-1C/1D, and matrix metallo-
proteinase 9 (MMP-9) (Fujimoto et al., 2005, 2006). They are
all regular basement membrane constituents, which possess a
large regulatory potency for enhancing or depressing a
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variety of functions, depending on the cellular or tissue
context (Mirancea et al., 2006, 2007). MMP-9 is a proteolytic
enzyme that has a catalytic activity against several extra-
cellular matrix components.
The human ECM1 gene consists of 11 exons spanning
approximately 5 kb, located at chromosome 1q21 (Johnson
et al., 1997; Smits et al., 1997), and encodes for four distinct
splice variants: ECM1a (without exon 5a, 540 amino acids
(aa)), which is expressed in the basal layer of the epidermis,
the dermal blood vessels, the outer root sheath of hair
follicles, and the sebaceous lobules and epithelium of sweat
glands; ECM1b (lacking exons 5a and 7, 415 aa), which is
expressed in the suprabasal layers (Smits et al., 2000; Oyama
et al., 2003; Sander et al., 2006); ECM1c, which is
homologous to the mouse full-length gene (559 aa) (Bhalerao
et al., 1995; Smits et al., 1997, 1999); and a recently
identified variant leading to a short protein of 57 aa (Horev
et al., 2005).
After the cloning of the ECM1 gene in 1997 (Smits et al.,
1997), its expression in human tissues and its pathogenic role
in human diseases, such as lipoid proteinosis and lichen
sclerosus, have been advocated. However, the biological
function of ECM1 in skin, as well as the pathophysiology of
lipoid proteinosis and lichen sclerosus, is not well under-
stood. Because of the restricted localization of each of the
four ECM1 isoforms in the skin components, we speculate
that ECM1 might be able to interact with other extracellular
matrix components, such as polysaccharides (hyaluronan
(HA), heparin, chondroitin sulfate A (CSA)) and proteins
(fibronectin (FN), LN, collagen IV), either as its reservoir or as
its cofactor.
RESULTS
ECM1a is capable of binding with different components of the
extracellular matrix
When the panel of different extracellular matrix components
was immobilized onto the surface of a microtiter plate,
recombinant human ECM1a bound to FN (Figure 1a), LN
(mainly LN 10) (Figure 1b), HA (Figure 1c), heparin (Figure
1d), CSA (Figure 1e), LN 332 (Figure 1f), and collagen IV
(Figure 1g), in a dose-dependent manner. Interestingly, their
binding capacity considerably varied among these proteins
and polysaccharides (maximum A450 ranged from 0.43 to
2.30); both FN and heparin seems to bind ECM1a much
stronger than LN 332, LN, and CSA, and collagen IV and HA
were the weakest. As control, we used phosphate-buffered
saline (PBS) or albumin (Figure 1h) without finding any
binding of ECM1a to albumin.
Unbound extracellular matrix components are capable of
competing with the binding of ECM1a to immobilized
extracellular matrix components
To determine if the binding represents a specific interaction
between ECM1a and the other extracellular matrix mole-
cules, two types of experiments were carried out. Experi-
ments with HA are representative (Figure 2c). First, ECM1a
was preincubated with free HA (with different concentra-
tions) and was then added to a HA-coated plate. As expected,
the free HA competed with the interaction between ECM1a
and immobilized HA in a dose-dependent manner. After
washing the ECM1a–free HA away complex, the anti-ECM1a
serum detected less ECM1a bound to the immobilized HA.
The higher concentration of free HA was presented, the lower
A450 value was measured. Indeed, this type of competition
was true with FN (Figure 2a), LN (mainly LN 10) (Figure 2b),
HA (Figure 2c), heparin (Figure 2d), CSA (Figure 2e), LN 332
(Figure 2f), and collagen IV (Figure 2g), indicating the specific
binding of ECM1a to each single extracellular molecule.
In the second set of experiments, ECM1a was added to an
LN-coated plate (mainly LN 10) before reacting with HA to
determine if HA could affect the binding of LN to ECM1a.
However, the free HA failed to interfere with the binding of
ECM1a to the immobilized LN (Figure 3a), evidenced by the
fact that the addition of excessive amounts of HA did not alter
the ECM1a binding (determined by anti-ECM1 serum),
presenting a much weaker binding between ECM1a and
HA (Figure 3a). Similar data were obtained when coated with
collagen IV (Figure 3b), confirming that the binding capacity
of ECM1a to LN is relatively tighter than those to poly-
saccharides and collagen IV, being similar to our primary
binding assay (Figure 1). Altogether, these data raise the
possibility that ECM1a may utilize different binding sites to
form a complex with certain extracellular molecules.
ECM1a enhances binding of collagen IV to immobilized LN 332
As the thickened blood vessel walls in the skin of patients
with lipoid proteinosis were stained strongly for type IV
collagen, LN, and perlecan (Mirancea et al., 2006), the key
components of the anchoring complex connecting the
keratinocytes to the underlying dermis (Rakhorst et al.,
2006; Schneider et al., 2006), we focused on these proteins
and hypothesized that collagen IV might bind to LN 332. The
binding data indicated that collagen IV, indeed, bound
to immobilized LN 332 in a dose-dependent manner
(Figure 4a). Interestingly, in the same binding system, the
addition of ECM1a was able to enhance the binding between
collagen IV and immobilized LN 332 (Figure 4b).
Binding of ECM1a fragments to LN 332 or collagen IV
To determine which part of ECM1a is responsible for the
binding to LN 332, four genetically engineered ECM1a
fragments, DS/ex7 (representing 203–350 aa), DDs/COOH
(representing 340–540 aa), DS/COOH (representing 480–540
aa), and DPx/COOH (representing 203–432 aa) (Figure 5a),
were added to an LN 332-coated plate, followed by detection
with the corresponding anti-ECM1a antibodies, Sp23, and the
anti-ECM1 polyclonal antibody OAP 12516. We found that
the DPx/COOH fragment had the highest binding capacity
among the four fragments (Figure 5b). When its C-terminal 83
aa was eliminated, the remaining part (DS/ex7) still retained
the binding capacity to LN 332. The same results were
obtained after coating the plates with different ECM1a
fragments before incubation with LN 332 (data not shown).
Both DDs/COOH and DS/COOH had a very faint binding
capacity, consistent with the control level, suggesting that
the C-terminal 200 aa did not contribute to the binding of
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LN 332. However, the binding pattern of these four fragments
to collagen IV was quite different in terms of the dose-
dependency and all reached a plateau at around 0.8
absorbance (Figure 5c), except for the full-length ECM1a,
implicating that the binding core of ECM1a with collagen IV
exclusively locates within the NH2-terminal portion (32–340
aa; DNH2) (Figure 5a). To address this site-specific binding,
the free DNH2 fragment was used to compete with the
binding of collagen IV and DNH2. The results demonstrated
that the amount of collagen IV bound to the immobilized
DNH2 was inversely correlated with the amount of free DNH2
(compare between Figure 6a and b), suggesting the specific
interaction between collagen IV and DNH2. Similar results
were obtained after coating the plates with the DNH2 ECM1
fragment before incubation with collagen IV (data not
shown).
Collectively, our results suggest that (i) the DS/ex7
(203–349 aa) fragment binds LN 332, (ii) the NH2-terminal
region (32–340 aa) is important for specific binding with
collagen IV, and (iii) the C-terminal region (340–540 aa) does
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Figure 1. Binding of ECM1a to the immobilized components of the extracellular matrix. One hundred microliters (per well) of 1 mgml1 highly purified
extracellular matrix protein ((a) FN, (b) LN, (f) LN 332, (g) collagen IV) or 100mgml1 polysaccharide ((c) HA, (d) heparin, (e) CSA) was coated on 96-well
microtiter plates. (h) PBS or albumin (2 mgml1) was coated on the 96-well plate as negative control. After blocking, the wells were incubated with 0.5 mgml1
full-length human recombinant ECM1a, then with affinity-purified rabbit anti-ECM1a antibodies and HRP-conjugated secondary IgGs, followed by
color development using TMB substrate. After stopping the reaction, the plates were analyzed by a plate reader at A450. The binding of ECM1a to each
extracellular matrix protein was in a dose-dependent manner (Student’s t-test: Po0.001 at the highest ECM1a dose). The bars are representative for the
standard deviation from three independent experiments.
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not contribute significantly to the potential binding with
either collagen IV or LN 332.
ECM1 is a component of basement membrane networks and
revealed colocalization with collagen IV and LN 332
Owing to the lack of information about ECM1a expression in
the basement membrane of human skin, we chose to
investigate the potential expression overlap of ECM1 with
collagen IV and LN 332 in this organ. After cotreating frozen
sections of human skin with an anti-ECM1 antiserum and
anti-LN 332 (Figure 7c) or anti-collagen IV (Figure 7e)
antibody, LN 332 expression showed colocalization with
ECM1 specific at the basement membrane (Figure 7d).
Colocalization of ECM1 with collagen IV is less marked
and some single spots of colocalization are visible (Figure 7e
and f).
Considering the in vitro binding of ECM1a with multiple
extracellular and basement membrane molecules, we
attempted to further examine whether ECM1a is involved in
the networks of the major basement membrane. Basement
membrane preparations from de-epithelialized human dermis
containing authentic suprastructural fragments were double-
immunolabeled using a combination of antibodies against
ECM1a/c and either collagen type IV or LN 332 or perlecan
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Figure 2. Competition of the binding between free and immobilized components of the extracellular matrix. A 100ml portion of a preincubated mixture
of ECM1a (0.5 mgml1) and different polysaccharides ((c) HA, (d) heparin, or (e) CSA at 500mgml1 as starting concentration and then a 1:2 serial dilution)
or proteins ((a) FN at 500mgml1; (b) LN, mostly LN 10, at 100mgml1; (f) LN 332 at 1 mgml1; and (g) collagen IV at 10mgml1 as starting concentration
and then a 1:2 serial dilution) were added to the corresponding component-coated plates. A preincubated mixture of ECM1a (0.2mgml1) together with different
concentrations of (f) LN 332 (0, 250, 500, and 1,000 ngml1) or (g) collagen IV proteins (0, 1.25, 2.5, 5, or 10 mgml1) was used for the second set of
experiments. The wells were incubated with anti-ECM1a antibodies and HRP-conjugated secondary IgGs, followed by color development. The unbound
form indeed competed with its immobilized form in a dose-dependent manner (Student’s t-test: Po0.01). The bars are representative for the standard
deviation from three independent experiments.
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as a control. Both basement membrane components com-
prise multiple isoforms forming two independent networks,
collagen IV and LN 332, interconnected by nidogen
(Battaglia et al., 1992; Mayer et al., 1993). Staining for
perlecan was used as an internal control, as its interaction
with ECM1 has been established by Mongiat et al. (2003).
Ultrastructurally, a colocalization of ECM1a/c with LN 332
(Figure 8a and b), collagen IV (Figure 8c and d), and perlecan
(Figure 8e and f) was found in the suprastructural skin
preparations. More importantly, most of the labeling for
ECM1a/c tended to colocalize with any two of the basement
membrane proteins, suggesting that ECM1a/c is part of both
collagen IV- and LN 332-containing network-like supras-
tructures of the skin basement membrane. The results were
further confirmed by immunoelectron microscopy using
ultrathin skin sections. A similar localization and distribution
of the labeling for ECM1 was revealed in the basement
membrane zone (Figure 9a) and the collagen IV networks of
the human skin (Figure 9b and c).
DISCUSSION
In this study, we demonstrate in vitro evidence that (1)
ECM1a can interact with several major extracellular matrix
and basement membrane proteins in the skin (such as
LN 332, collagen IV, LN (mainly LN 10), and FN), and
polysaccharides (such as HA, heparin, and CSA). This
conclusion is based on the dose-dependent binding of
ECM1a to immobilized extracellular matrix components
and the competitive inhibition of this specific binding with
unbound equivalents. (2) ECM1a enhances the basal binding
affinities between collagen IV and LN 332, presumably via
a complex formation (polymerization) between these three
molecules. (3) ECM1a utilizes different sites to bind to
collagen IV or LN 332. The NH2-terminal region (32–340 aa)
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of ECM1a is critical for specific binding of collagen IV. In
contrast, the more downstream region (203–340 aa), termed
ECM1 tandem repeat domains (Bhalerao et al., 1995) (Figure
10a), preferentially binds to LN 332. To our knowledge, these
findings are previously unreported. Considering that the
overall binding experiments were carried out at physiological
conditions, such as pH 7.2–7.4 and physical osmosis, it is
conceivable that the interaction may occur in vivo. In an
alternative approach to find binding partners for ECM1a, LN
332 was also found in a yeast two-hybrid screen of a human
epidermal cDNA library with ECM1a as bait and proven to
interact with ECM1a using in vitro co-immunoprecipitation
experiments (S Sercu, submitted).
We have used de-epithelialized human skin for one of the
colocalization studies because we wanted to analyze the
morphology and composition of authentic supramolecular
fragments derived from the dermal–epidermal junction zone.
This well-established method has the advantage of getting
authentic suprastructures without any fixation, which very
often changes the real situation in tissue. The only
disadvantage of the method is the loss of orientation of the
isolated suprastructures within the tissue. Therefore, in
addition, we used ultrathin sections to get an idea about
the orientation within the tissue. The results from the different
localization studies support the possible in vivo interrelation-
ship between collagen IV and LN 332. Surprisingly, most
signals for ECM1 colocalized with those for collagen IV or LN
332, as well as perlecan (Figures 8 and 9), suggesting that
ECM1 is exclusively involved in two independent supras-
tructure networks, containing either LN 332 or collagen IV,
at the basal lamina.
The C terminus of ECM1 has been shown to bind speci-
fically with EGF-like modules flanking the LG2 subdomain
of perlecan domain V (Mongiat et al., 2003). Perlecan is an
intrinsic component of basement membranes, and is also
involved in the binding with interstitial dermal components,
such as FN, LNs, collagen IV, fibulin-2, and heparin (Sasaki
et al., 1995; Hopf et al., 2001). These interactions may play a
role in the extracellular matrix assembly around the
ECM 1 ECM 1
ECM 1/LN 332 ECM 1/LN 332
ECM 1:collagen IVECM 1/collagen type IV
Figure 7. Colocalization of ECM1 with LN 332 and collagen type IV in the
basal layer of the epidermis. Two-week old air-exposed organotypic
keratinocyte (a) monocultures or (b–f) cocultures were stained for antibodies
against ECM1 (OAP 12516). Colocalization (orange; arrows) of ECM1
(green) with LN 332 (red) and collagen type IV (red) in the basal-cell layers.
Bars¼ 50 mm. d and f are enlargements from areas of the shown section.
a
b c
d e
f
Figure 8. Ultrastructural localization of ECM1 in human basement
membrane networks. Double immunogold-labeling of human skin
suprastructural fragments from de-epithelialized human dermis (a and b)
with antibodies against ECM1a/c and LN 332, (c and d) with those against
ECM1a/c and collagen IV, and (e and f) with those against ECM1a/c and
perlecan. The large (18 nm, arrowheads) and small gold particles (12 nm,
arrows) indicate the labeling for ECM1a/c and the other extracellular proteins,
respectively. Note that the ECM1a/c and other extracellular proteins are
part of the same matrix suprastructures. Bars¼100 nm.
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dermal–epidermal junction. Moreover, the tandem repeat
domains of ECM1 show in vitro binding with fibulin-1C/1D
(Fujimoto et al., 2005) and MMP-9 (Fujimoto et al., 2006).
Interaction between ECM1 and MMP-9 results in a negative
regulatory effect for the enzymatic activity, as assessed by a
gelatin-based ELISA. Although the formal proof whether these
interactions are physiologically relevant awaits further in vivo
experimentation. The precise molecular mechanisms of
ECM1 binding to fibulin-1C/1D and MMP-9 are still
unknown. Nevertheless, these data strongly support our
finding that ECM1a is capable of binding with multiple skin
extracellular matrix molecules.
Taken together, our present data clearly illustrate the
complex formation between collagen IV and LN 332
(Figure 4). These two are pivotal structural proteins in the
skin basement membrane, facilitating the epidermal–dermal
assembly; LN 332 is a major anchoring molecule at the base
of anchoring filaments in the upper lamina densa/lamina
lucida of the basement membrane, whereas the basal
membrane is mainly composed of collagen IV within the
basal lamina (Figure 10b) (McMillan et al., 2003). Interest-
ingly, our binding experiments show that LN 332 interacts
with collagen IV and that ECM1a is able to enhance this
binding (Figure 4). However, this is in contrast with the
findings reported by Rousselle et al. (1997). Recently, McKee
et al. (2007) showed that type IV collagen recruitment into
the LN 111 extracellular matrices appears to be mediated
through a nidogen bridge (Fox et al., 1991; Yurchenco and
O’Rear, 1994; Yurchenco et al., 2004) and a lesser
contribution arising from a direct interaction with LN 111.
They also suggested that collagen IV binds other LNs. Our
ELISA-based binding studies suggest that collagen IV is linked
to LN 332 through ECM1a, which binds to the two proteins
and enhances their binding. It is possible that ECM1a
functions as a bridging core stabilizing these two hemi-
desmosomal molecules, thereby linking them to each other.
This could support the formation of the basic framework and/
or physiological flexibility in the skin basement membrane.
We propose that ECM1 acts as a ‘‘biological glue’’ in the
basement membrane of the skin to maintain the structural
and functional skin integrity (Chan et al., 2004b). The most
persuasive observation for this concept includes that ECM1a
encompasses multiple epitopes for binding with various
extracellular matrix/hemidesmosomal molecules of the
epidermal basement membrane (Figure 10).
Of note, all binding assays described in this study are
performed with recombinant human ECM1a protein.
Whether this holds true for the ECM1c splice variant, differing
from ECM1a by an additional 19 amino acids encoded by
exon 5a, needs still to be investigated. The amount of ECM1c
mRNA was estimated to be 15% of the total amount of ECM1
mRNA in two different cell lines (HT1080 and A431)
(Mongiat et al., 2003). Antibodies able to discriminate
between all ECM1 isoforms are not currently available.
The most striking evidence for ECM1 playing a role in skin
represents loss-of-function mutations of the ECM1 gene
causing an autosomal-recessive disorder lipoid proteinosis,
characterized by profound alterations of the basement
membrane/dermal extracellular matrix behavior, particularly
in skin (Hamada et al., 2002, 2003; Teive et al., 2004; Van
Hougenhouck-Tulleken et al., 2004; Horev et al., 2005;
Kowalewski et al., 2005). The resulting ECM1 dysfunction
causes instability of the extracellular matrix and basement
membrane assembly in conjunction with decreased enzy-
matic activity of MMP-9—via aberrant increase of collagen
IV and LNs, which are both binding partners of ECM1a—
leading to hyaline (glassy) material deposits and dilated blood
vessels in the dermis, finally reflecting the major mucocuta-
neous manifestations of the disease (Mirancea et al., 2006).
Another rationale for ECM1 function in skin integrity is
the identification of serum auto-antibodies targeting ECM1
in lichen sclerosus, a chronic inflammatory state that affects
skin and mucous membranes. This disease has a charac-
teristic skin pathology, mostly consistent with that of lipoid
LL
a
b
c
LD
LD
col
col
Figure 9. Ultrastructural localization of ECM1 in the human skin basement
membrane. Double immunogold-labeling of human skin ultrathin sections
with antibodies against ECM1a/c (18 nm gold particles, arrowheads) and
collagen IV (12 nm gold particles, arrows). ECM1a/c is a component of
the basement membrane zone (a) and part of the collagen IV-containing
networks of the basement membrane of human skin (b and c). Note that
both ECM1a/c and collagen IV colocalized in the skin basement membrane,
which is clearly visible on the tangential section of the basement
membrane zone. LL, lamina lucida; LD, lamina densa; col, collagen
fibrils. Bars¼100 nm.
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proteinosis (Chan et al., 2004a). Immunologically, more than
70% of lichen sclerosus patients had IgGs reactive with the
DDs/COOH portion of ECM1a (340–540 aa) and, more
importantly, the DDs/COOH-reactive patients’ sera fre-
quently contained IgGs against the DNH2 part, suggesting
heterogeneous IgG reactivity to spared antigenic epitopes
within ECM1 (Smits et al., 2000). In contrast, most ECM1
mutations in lipoid proteinosis have been detected in exon 7,
a region spliced out in ECM1b, whereas nonsense or out-of-
frame mutations have been detected in exon 6, causing
deletion of exon 7 and its downstream region. Combining
clinical and our basic research data, one may speculate that
anti-ECM1 IgGs in lichen sclerosus patients affect the
functional binding of ECM1 with collagen IV and perlecan,
whereas lipoid proteinosis mutations mainly affect the
binding of ECM1 with LN 332, MMP-9, fibulin-1C/1D, and
perlecan. The reaction chain may affect further damages
in the interaction between ECM1 and other extracellular
matrix components, ultimately contributing to the mimicking
clinicopathology in both disease conditions.
In summary, we have demonstrated that ECM1a has
promiscuous interactions with multiple major basement
membrane components in human skin, implying its compli-
cated and important function(s) in the epidermal–dermal
interface physiology (Figure 10). Further research is necessary
to identify the crucial ECM1 protein interaction partners as
well as to define structurally the binding site(s) of ECM1 with
LN 332 and collagen IV for understanding the complex ECM1
communication in skin.
MATERIALS AND METHODS
Reagents
HA (H1876), heparin (H4784), CSA (C9819), human LN (mostly
LN 10) (L6274), and FN (F2006) were purchased from Sigma Inc.
(St Louis, MO), human collagens III and IV from Chemicon
International Inc. (Temecula, CA), and LN 332 from Immun-
diagnostik AG (Bensheim, Germany). Four recombinant ECM1a
fragments were purified as described previously (Oyama et al.,
2004). Mouse mAbs against human collagen types III and IV, LN,
and FN were purchased from EMD Biosciences Inc. (San Diego, CA).
The full-length recombinant ECM1a and rabbit anti-ECM1-specific
antibodies (OAP 12516, Sp23, and epidermal differentiation factor)
were purified as previously described (Smits et al., 2000; Han et al.,
2001). HA binding protein was purified and labeled with biotin as
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Figure 10. Summary of the different binding partners of ECM1 in the dermal–epidermal junction. (a) Site-specific binding of ECM1a to different
hemidesmosomal and extracellular matrix molecules. ECM1a is capable of binding different extracellular matrix proteins with different binding sites. It is
known that domain V of perlecan interacts with the C terminus of ECM1 (424–540 aa) (Mongiat et al., 2003), whereas fibulin-1C/1D and MMP-9 bind to the
tandem repeat region of ECM1 (236–361 aa) (Fujimoto et al., 2005, 2006), which is also capable of binding LN 332 (207–340 aa; Figures 1 and 2). Collagen IV
interacts with the NH2 domain of ECM1 (14–207 aa; Figure 6) and also with LN 332 (Figure 5), and these interactions could be enhanced by ECM1 (Figure 4).
The Sp23 antibody recognizes an epitope encoded by 287–300 aa, whereas OAP12156 was raised against recombinant human ECM1a and could attack
different epitopes (Smits et al., 2000). (b) Schematic representation of the in vivo binding partners of ECM1 in the dermal–epidermal junction. In the basal layer
of human epidermis, keratinocytes are anchored to the basement membrane by monomeric or polymeric proteins, forming hemidesmosomes. Some of
these proteins are secreted by keratinocytes as well as fibroblasts (heparin, perlecan, and FN) and are directly connected to ECM1. Other structural
proteins localize specifically in the lamina lucida (LN 332 and fibulin-1) or in the lamina densa of the basement membranes (LN 332 and collagen IV).
Major interstitial dermal proteins/polysaccharides contain FN, CSA, and HA, which bind to ECM1 with different affinities. MMP-9, which has a proteolytic
activity for collagen IV, is capable of binding to ECM1, although this specific binding could downregulate the enzymatic activity (Amano et al., 2001).
As illustrated, ECM1 can act as a ‘‘biological glue’’ in the whole basic framework and physical flexibility in human skin.
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described previously (Underhill and Zhang, 2000). The following
antibodies have been used: guinea-pig polyclonal antibody to
plectin (Acris Antibodies GmbH, Hiddenhausen, Germany) and
mouse mAbs to integrin a-6 (MPF410; R&D Systems, Minneapolis,
MI), integrin b-4 (3E1; Chemicon International Inc.), type VII
collagen (LH7.2; Sigma Inc.), g-2 chain of LN 332 (GB3; Abcam,
Cambridge, UK), and the cytoplasmic domain of BP180 (1A8C;
kindly provided by Dr Owaribe, Okazaki, Japan). Cy3- or FITC-
conjugated antibodies (Dako, Cambridgeshire, UK) against collagen
IV for the immunogold labeling (MAB 1910; Chemicon International
Inc.), against collagen IV for the immunohistochemistry (LH 7.2;
Dr IM Leigh, London, UK), LN 332 for the immunogold labeling
(6F12) and for the immunohistochemistry (Chemicon International
Inc.) or perlecan (MAB 1948; Chemicon International Inc.), diluted
in PBS containing 0.2% Aurion BSA-c (Biotrend, Cologne,
Germany), were used.
Binding of ECM1a to various extracellular matrix proteins
One hundred microliters of different polysaccharides (HA, heparin,
and CSA at 100mgml1) and proteins (LN (mainly LN 10), LN 332,
and FN at 1 mgml1 and collagen IV at 10 mgml1) were coated on a
high-bound 96-well microtiter plate at room temperature (RT) for
1 hour or 4 1C overnight. After blocking with 360 ml per well of 2%
(w/v) BSA (Sigma Inc.), the plates were washed with 0.01% (v/v)
PBS-T (Tween-20, pH 7.2) three times and incubated with human
recombinant ECM1a (0.5 mgml1) at 4 1C overnight. After washing,
the wells were incubated with 100ml of affinity-purified rabbit
anti-ECM1 serum (1:1.000 diluted in 0.5% (w/v) BSA–PBS) at RT for
3 hours, then with 100 ml of 1:2,000 horseradish peroxidase (HRP)-
conjugated anti-rabbit IgGs, followed by reacting with HRP substrate
TMB (3,30,5,50-tetramethylbenzidine, Sigma Inc.). The reaction was
stopped with 50 ml of 2 N H2SO4 and measured at A450. In the overall
binding assays, optimal conditions (that is, sample concentrations,
reaction conditions, and so on) were established by various
chessboard titrations. As a negative control, PBS or albumin
(2mgml1) was coated on the high-bound 96-well microtiter plate
followed by the addition of ECM1 (1 mgml1) and anti-ECM1.
Similarly, rhECM1a (2mgml1) was coated onto the plate followed
by the addition of albumin.
Competition binding assay
One hundred microliters of different polysaccharides (HA, heparin,
and CSA at 100mgml1) and proteins (LN and FN at 1mgml1) were
coated on a high-bound 96-well microtiter plate. The wells were
incubated at RT for 3 hours with 100ml of a preincubated mixture
(RT for 0.5 hours) of ECM1a (0.5 mgml1) together with different
polysaccharides (HA, heparin, or CSA at 500mgml1 as starting
concentration and then 1:2 serial dilution) or proteins (LN at
100mgml1 and FN at 500mgml1 as starting concentration and
then 1:2 serial dilution). For the second experiment, we used 100ml
of LN 332 (1 mgml1) or collagen IV (10 mgml1) to coat the plate,
and then 100 ml of a preincubated mixture consisted of ECM1a
(0.2 mgml1) and different concentrations of either collagen IV
(0, 1.25, 2.5, 5, or 10 mgml1) or LN 332 (0, 250, 500, and
1,000ngml1). The wells were incubated with affinity-purified
anti-ECM1 serum, followed by reacting with 100ml of 1:2,000
HRP-conjugated anti-rabbit IgGs and color development in a similar
manner.
Binding enhancement assay
A binding assay was carried out on two sets of samples. In the
first experiment, 100 ml of LN 332 (1 mgml1) was coated on a high-
bound 96-well microtiter plate at RT or 4 1C overnight. After
blocking, the wells were incubated with different concentrations of
human collagen IV (0, 1.25, 2.5, 5, or 10 mgml1) at 4 1C overnight.
For the second experiment, we performed an additional incubation
with ECM1a at a final concentration of 0.2mgml1 before incubation
with various concentrations of human collagen IV (0, 1.25, 2.5, 5, or
10 mgml1) on LN 332-coated wells at 4 1C overnight. The wells
were then incubated with 100 ml of affinity-purified rabbit anti-ECM1
serum (1:1.000 diluted in 0.5% (w/v) BSA–PBS) at RT for 2 hours,
followed by the same procedures for color development.
Binding of ECM1a fragments to LN 332 or collagen IV
In the first experiment, 100ml of LN 332 (1mgml1) or collagen IV
(10 mgml1) in PBS was coated onto a microtiter plate at RT for
1 hour or at 4 1C overnight. After blocking, the wells were incubated
with different concentrations (0.5, 0.25, 0.125, 0.062, 0.031, and
0.015mgml1) of four human recombinant ECM1a fragments
(DS/ex7, DDs/COOH, DS/COOH, DPx/COOH) at 4 1C overnight,
then with 100ml of the corresponding anti-ECM1 antibodies (1:1.000
diluted in 0.5% (w/v) BSA–PBS) at RT for 3 hours, followed by the
same procedures for color development. This experiment was also
performed the other way around. A set of purified recombinant
human ECM1 fragments (as indicated) were coated onto the ELISA
plate at different concentrations (0.031, 0.062, 0.125, 0.25, 0.5, and
1mgml1) at 4 1C overnight. After blocking, the purified human LN
332 (0.5 mgml1) in 0.1% Tween-20 was added to each well and
incubated at RT for 2 hours, followed by 0.5 mgml1 monoclonal
anti-LN V, 0.1 mgml1 HRP-anti-mouse IgG, and TMB substrate.
In the second experiment, 100ml of the human recombinant
ECM1a fragment DNH2 (10mgml
1) was coated onto the microtiter
plate at RT or at 4 1C overnight, and blocked with 360ml per well of
0.1% BSA with 5% Tween-20 for 1 hour. After washing, the wells
were incubated with different concentrations of human collagen IV
(0, 0.156, 0.312, 0.625, 1.25, 2.5, or 5 mgml1 at 4 1C overnight),
then with 100 ml of biotinylated affinity-purified rabbit anti-collagen
IV IgGs (1:1.000 diluted in 0.5% (w/v) BSA–PBS, 0.1% (v/v) Tween-
20) at RT for 2 hours, followed by reacting with streptavidin/HRP-
conjugated anti-rabbit IgGs, and color development.
Competition binding assay with the DNH2 fragment
One hundred microliters of recombinant DNH2 (10 mgml
1) was
coated onto a high-bound 96-well microtiter plate at RT overnight.
After blocking, the wells were incubated with a serially diluted
DNH2 (3.12, 6.25, 12.5, 25, or 50mgml
1) together with collagen IV
(5mgml1) at 4 1C overnight. In this condition, the free DNH2 can act
as a competitor for the binding of immobilized DNH2 and collagen
IV. After washing, the wells were incubated with 100 ml of 1:1.000
biotinylated affinity-purified rabbit anti-collagen IV IgGs at RT for
2 hours, then followed by reacting with streptavidin/HRP-conjugated
anti-rabbit IgGs and color development.
Dermal extracts
Normal human skin was obtained from patients, with informed
consent, who underwent plastic surgery. Isolation of authentic
supramolecular fragments from the dermal–epidermal junction zone
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was performed as previously described (Kassner et al., 2003). Briefly,
the epidermal layer was removed after treatment with neutral buffer
containing 1M NaCl for 4 hours, and the separated dermal layer was
frozen in liquid nitrogen. A layer of 200 mm was removed from the
dermal surface by a dermatome, and repeatedly homogenized
in 150mM NaCl and 2mM sodium phosphate buffer (pH 7.4)
containing a mixture of protease inhibitors. Between each homo-
genization step, tissue debris was removed by low-speed centrifuga-
tion. The resultant supernatants containing supramolecular
fragments from the dermal–epidermal junction were used for analysis
by electron microscopy.
Ultrathin sections of human skin
Freshly obtained human skin was taken with the consent of the
patient, sliced into small pieces, and fixed in 4% (w/v) paraformal-
dehyde and 0.25% (w/v) glutaraldehyde in 100mM sodium
cacodylate buffer (pH 7.4) at 41C. The samples were rinsed in
PBS, dehydrated in an ascending series of ethanol from 30% (v/v) to
70% (v/v), and embedded in the acrylic resin LR White (London
Resin Company, London, UK). Ultrathin sections were cut with an
ultramicrotome and collected on uncoated copper grids for
immunoelectron microscopy.
Immunogold electron microscopy
For immunogold electron microscopy, aliquots of fibrillar extracts
from skin taken with the consent of the patient were adsorbed for
5minutes to nickel grids coated with Formvar/carbon. The grids
were subsequently washed with PBS and treated with 5% BSA (w/v)
in PBS. The absorbed suprastructures were allowed to react for
2 hours with polyclonal antibodies against ECM1a (OAP 12516 or
Sp23) and mAbs against collagen IV, LN 332, or perlecan, those of
which were diluted in PBS containing 0.2% Aurion BSA-c (Biotrend)
and 0.1% (v/v) Tween 20 (blocking solution). After washing with the
blocking solution, the grids were put on drops of the blocking
solution containing goat antibodies to rabbit and mouse IgGs
conjugated to 12 and 18 nm gold particles, respectively (diluted
1:30; Jackson Immuno Research Laboratories, Cambridgeshire, UK).
Finally, the grids were washed with distilled water and stained with
2% (w/v) uranyl acetate for 10minutes.
For the ultrathin sections of human skin, the skin sections taken
with patient consent were first treated with 100mM glycin in PBS for
2minutes, washed twice in PBS, and blocked with 2% (w/v) BSA in
PBS for 30minutes. They were treated for 2 hours at RT with
polyclonal antibodies against ECM1 (diluted 1:100 in 0.2% BSA in
PBS) and with mAbs against collagen IV (diluted 1:50 in 0.2% (w/v)
BSA in PBS), and then with gold-conjugated antibodies against rabbit
IgGs (18 nm gold particles) and mouse IgGs (12 nm gold particles),
finally followed by staining with uranyl acetate for 8minutes.
Control experiments were performed with the second antibody
alone. Electron micrographs were taken at 60 kV with an EM-410
electron microscope (Philips).
Immunohistochemistry
Using the snap-frozen sections from 2-week-old cultured skin
equivalents, the expression of ECM1 was visualized with the rabbit
polyclonal antibodies epidermal differentiation factor and OAP
12516, which recognize all ECM1 isoforms as described previously
(Smits et al., 2000). The OAP 12516 antibody was used in a 1:100
dilution, whereas epidermal differentiation factor antibodies were
used in a 1:400 dilution.
For double-immunolabeling of ECM1 (OAP 12516) with collagen
type IV and LN 332, tissues were fixed in acetone for 10minutes and
preincubated for 30minutes with 5% NHS (normal horse serum).
Tissues were incubated with anti-mouse collagen type IV and LN
332 (1:70), followed by incubation with goat-anti-mouse Cy3
(1:200) (Jackson Immuno Research Laboratories). After washing,
the samples were incubated overnight with anti-rabbit ECM1. The
next day, sections were incubated with goat-anti-rabbit FITC (1:100)
(Serotec, Oxford, UK) for 30minutes and 40,6-diamidino-2-phenyl-
indole (1:1.000) (DAPI; Molecular Probes, Invitrogen, Breda,
The Netherlands) for 3minutes. Finally, tissue samples were
mounted with Vectashield (Brunschwig Chemie, Amsterdam,
The Netherlands) and coverslipped.
All the studies were approved by the Institutional Research Ethics
Committee and adhered to the Declaration of Helsinki Principles.
Statistics
In all binding assays, a comparison of the ELISA value between each
single additive was analyzed by Student’s t-test. The value less than
0.05 was considered statistically significant.
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